MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE 1 in the 9q22 thyroid cancer risk locus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 3, 2017, Pages 474-479

  Wang, Yanqiang ^a   He, Huiling ^a   Li, Wei ^a   Phay, John ^a   Shen, Rulong ^a   Yu, Lianbo ^b   Hancioglu, Baris ^b   De La Chapelle, Albert ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Bidirectional promoter; LncRNA; MYH9; Thyroid cancer; Transcriptional regulation

Indexed keywords

FORKHEAD BOX PROTEIN E1; FORKHEAD TRANSCRIPTION FACTOR; LONG UNTRANSLATED RNA; LONG UNTRANSLATED RNA PAPILLARY THYROID CANCER SUSCEPTIBILITY CANDIDATE 2; MYOSIN; MYOSIN 9; PROTEIN P53; RNA; UNCLASSIFIED DRUG; FOXE1 PROTEIN, HUMAN; MOLECULAR MOTOR; MYH9 PROTEIN, HUMAN; MYOSIN HEAVY CHAIN; PROTEIN BINDING;

CANCER GENETICS; CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GENE SILENCING; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIMARY CELL LINE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SUPPRESSOR GENE; THYROID CANCER CELL LINE; THYROID GLAND TISSUE; THYROID PAPILLARY CARCINOMA; TRANSCRIPTION REGULATION; ANTAGONISTS AND INHIBITORS; BINDING SITE; CHROMOSOME 9; GENE KNOCKDOWN; GENETIC PREDISPOSITION; GENETICS; METABOLISM; PAPILLARY CARCINOMA; THYROID TUMOR; TUMOR CELL LINE;

BINDING SITES; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 9; FORKHEAD TRANSCRIPTION FACTORS; GENE KNOCKDOWN TECHNIQUES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR MOTOR PROTEINS; MYOSIN HEAVY CHAINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RNA, LONG NONCODING; THYROID NEOPLASMS;

EID: 85009812360     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1619917114     Document Type: Article

References (51)

1. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295(18):2164-2167.
2. Gudmundsson J, et al. (2009) Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 41(4):460-464.
3. Gudmundsson J, et al. (2012) Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet 44(3):319-322.
4. Ai L, et al. (2014) Associations between rs965513/rs944289 and papillary thyroid carcinoma risk: A meta-analysis. Endocrine 47(2):428-434.
5. Takahashi M, et al. (2010) The FOXE1 locus is a major genetic determinant for radiation- related thyroid carcinoma in Chernobyl. Hum Mol Genet 19(12):2516-2523.
6. Matsuse M, et al. (2011) The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet 48(9):645-648.
7. Zhu H, Xi Q, Liu L, Wang J, Gu M (2014) Quantitative assessment of common genetic variants on FOXE1 and differentiated thyroid cancer risk. PLoS One 9(1):e87332.
8. Wang YL, et al. (2013) Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. J Med Genet 50(10):689-695.
9. Denny JC, et al. (2011) Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: Using electronic medical records for genome- and phenomewide studies. Am J Hum Genet 89(4):529-542.
10. Zannini M, et al. (1997) TTF-2, a new forkhead protein, shows a temporal expression in the developing thyroid which is consistent with a role in controlling the onset of differentiation. EMBO J 16(11):3185-3197.
11. De Felice M, et al. (1998) A mouse model for hereditary thyroid dysgenesis and cleft palate. Nat Genet 19(4):395-398.
12. Fernández LP, López-Márquez A, Santisteban P (2015) Thyroid transcription factors in development, differentiation and disease. Nat Rev Endocrinol 11(1):29-42.
13. De Felice M, Di Lauro R (2011) Minireview: Intrinsic and extrinsic factors in thyroid gland development: An update. Endocrinology 152(8):2948-2956.
14. Landa I, et al. (2009) The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet 5(9):e1000637.
15. He H, et al. (2015) Genetic predisposition to papillary thyroid carcinoma: Involvement of FOXE1, TSHR, and a novel lincRNA gene, PTCSC2. J Clin Endocrinol Metab 100(1):E164-E172.
16. MondM, et al. (2015) Somatic mutations of FOXE1 in papillary thyroid cancer. Thyroid 25(8):904-910.
17. Derrien T, et al. (2012) The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression. Genome Res 22(9):1775-1789.
18. He H, et al. (2015) Multiple functional variants in long-range enhancer elements contribute to the risk of SNP rs965513 in thyroid cancer. Proc Natl Acad Sci USA 112(19):6128-6133.
19. Conti MA, Adelstein RS (2008) Nonmuscle myosin II moves in new directions. J Cell Sci 121(Pt 1):11-18.
20. Wang Y, et al. (2016) Primary cell culture systems for human thyroid studies. Thyroid 26(8):1131-1140.
21. Hwang CI, et al. (2011) Wild-type p53 controls cell motility and invasion by dual regulation of MET expression. Proc Natl Acad Sci USA 108(34):14240-14245.
22. Fridman JS, Lowe SW (2003) Control of apoptosis by p53. Oncogene 22(56): 9030-9040.
23. Iyer MK, et al. (2015) The landscape of long noncoding RNAs in the human transcriptome. Nat Genet 47(3):199-208.
24. Jendrzejewski J, et al. (2012) The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc Natl Acad Sci USA 109(22):8646-8651.
25. Yoon H, et al. (2007) Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int J Cancer 121(4):767-775.
26. Sellers JR (2000) Myosins: A diverse superfamily. Biochim Biophys Acta 1496(1):3-22.
27. Fujita T, Kitaura F, Fujii H (2015) A critical role of the Thy28-MYH9 axis in B cell-specific expression of the Pax5 gene in chicken B cells. PLoS One 10(1):e0116579.
28. Zhao B, et al. (2015) The non-muscle-myosin-II heavy chain Myh9 mediates colitisinduced epithelium injury by restricting Lgr5+ stem cells. Nat Commun 6:7166.
29. Schramek D, et al. (2014) Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science 343(6168):309-313.
30. Beck CF, Warren RA (1988) Divergent promoters, a common form of gene organization. Microbiol Rev 52(3):318-326.
31. Trinklein ND, et al. (2004) An abundance of bidirectional promoters in the human genome. Genome Res 14(1):62-66.
32. Seila AC, et al. (2008) Divergent transcription from active promoters. Science 322(5909):1849-1851.
33. Pickrell JK, et al. (2010) Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature 464(7289):768-772.
34. Neil H, et al. (2009) Widespread bidirectional promoters are the major source of cryptic transcripts in yeast. Nature 457(7232):1038-1042.
35. Berretta J, Pinskaya M, Morillon A (2008) A cryptic unstable transcript mediates transcriptional trans-silencing of the Ty1 retrotransposon in S. cerevisiae. Genes Dev 22(5):615-626.
36. Camblong J, Iglesias N, Fickentscher C, Dieppois G, Stutz F (2007) Antisense RNA stabilization induces transcriptional gene silencing via histone deacetylation in S. cerevisiae. Cell 131(4):706-717.
37. Uesaka M, et al. (2014) Bidirectional promoters are the major source of gene activation- associated non-coding RNAs in mammals. BMC Genomics 15:35.
38. Abu-Khudir R, et al. (2014) Role for tissue-dependent methylation differences in the expression of FOXE1 in nontumoral thyroid glands. J Clin Endocrinol Metab 99(6): E1120-E1129.
39. Santisteban P, Acebrón A, Polycarpou-Schwarz M, Di Lauro R (1992) Insulin and insulin- like growth factor I regulate a thyroid-specific nuclear protein that binds to the thyroglobulin promoter. Mol Endocrinol 6(8):1310-1317.
40. Venza I, et al. (2011) MSX1 and TGF-beta3 are novel target genes functionally regulated by FOXE1. Hum Mol Genet 20(5):1016-1025.
41. Pilli T, Prasad KV, Jayarama S, Pacini F, Prabhakar BS (2009) Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer. Thyroid 19(12):1333-1342.
42. Sid B, et al. (2004) Thrombospondin 1: A multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 49(3):245-258.
43. Nucera C, et al. (2010) B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression. Proc Natl Acad Sci USA 107(23):10649-10654.
44. Duquette M, Sadow PM, Lawler J, Nucera C (2013) Thrombospondin-1 silencing downregulates integrin expression levels in human anaplastic thyroid cancer cells with BRAF(V600E): New insights in the host tissue adaptation and homeostasis of tumor microenvironment. Front Endocrinol (Lausanne) 4:189.
45. Sid B, et al. (2008) Thrombospondin-1 enhances human thyroid carcinoma cell invasion through urokinase activity. Int J Biochem Cell Biol 40(9):1890-1900.
46. Baxter RC (2014) IGF binding proteins in cancer: Mechanistic and clinical insights. Nat Rev Cancer 14(5):329-341.
47. Dulyaninova NG, House RP, Betapudi V, Bresnick AR (2007) Myosin-IIA heavy-chain phosphorylation regulates the motility of MDA-MB-231 carcinoma cells. Mol Biol Cell 18(8):3144-3155.
48. Kim D, et al. (2013) TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol 14(4):R36.
49. Liao Y, Smyth GK, Shi W (2014) featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30(7):923-930.
50. Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550.
51. Gordon A, Glazko G, Qiu X, Yakovlev A (2007) Control of the mean number of false discoveries, Bonferroni and stability of multiple testing. Ann Appl Stat 1(1):179-190.